What is the appropriate colchicine dosing regimen for an adult with an acute gout flare and for prophylaxis, including dose adjustments for renal or hepatic impairment and for pediatric patients?

Colchicine Dosage

For acute gout flares, use low-dose colchicine: 1.2 mg immediately, followed by 0.6 mg one hour later, then stop—do not continue dosing beyond this initial regimen. 1, 2, 3

Acute Gout Flare Treatment

The FDA-approved dosing for acute gout is 1.2 mg (two 0.6 mg tablets) at the first sign of flare, followed by 0.6 mg (one tablet) one hour later 3. This totals 1.8 mg over one hour, with a maximum of 1.8 mg per treatment course 1, 2.

This low-dose regimen is equally effective as the older high-dose regimen (4.8 mg over 6 hours) but causes significantly fewer gastrointestinal adverse events 4. In the pivotal trial, 37.8% of patients achieved ≥50% pain reduction at 24 hours with low-dose colchicine versus 15.5% with placebo, while the adverse event profile was indistinguishable from placebo 4.

Critical timing: Patients should self-administer at the earliest sign of flare onset—ideally within 12 hours—using a "pill-in-pocket" strategy 1, 5.

Do not repeat treatment courses more frequently than every 3 days 3.

Prophylaxis During Urate-Lowering Therapy

Standard dose: 0.6 mg once or twice daily (maximum 1.2 mg/day) 1, 3.

Prophylaxis should be initiated when starting urate-lowering therapy (allopurinol, febuxostat, pegloticase) and continued for at least 6 months 1, 2. Recent evidence shows 0.5 mg daily is as effective as 1 mg daily for preventing flares, with comparable safety 6.

Renal Impairment Adjustments

Prophylaxis:

• Mild impairment (CrCl 50-80 mL/min): No adjustment needed; monitor closely 3
• Moderate impairment (CrCl 30-50 mL/min): No dose adjustment required, but close monitoring essential; consider 0.3 mg daily if tolerability concerns 3
• Severe impairment (CrCl <30 mL/min): Start 0.3 mg daily 3
• Dialysis: 0.3 mg twice weekly 3

Acute Flare Treatment:

• Mild-to-moderate impairment: Standard 1.8 mg dose acceptable; monitor closely 3
• Severe impairment: Use standard dose but do not repeat more frequently than every 2 weeks 3
• Dialysis: Single dose of 0.6 mg only; do not repeat more frequently than every 2 weeks 3

Important caveat: Do not treat acute flares with colchicine in patients with renal impairment who are already receiving colchicine prophylaxis 3.

Hepatic Impairment Adjustments

Prophylaxis:

• Mild-to-moderate: No adjustment required; monitor closely 3
• Severe: Reduce dose; close monitoring required 3

Acute Flare Treatment:

• Mild-to-moderate: Standard dose acceptable 3
• Severe: Standard dose but do not repeat more frequently than every 2 weeks 3

Drug Interactions Requiring Dose Reduction

Colchicine is contraindicated with strong CYP3A4 or P-gp inhibitors in patients with renal or hepatic impairment 2, 3.

Strong CYP3A4 Inhibitors (clarithromycin, ketoconazole, ritonavir, atazanavir):

• Prophylaxis: Reduce from 0.6 mg twice daily to 0.3 mg once daily; or from 0.6 mg once daily to 0.3 mg every other day 3
• Acute flare: Reduce from 1.8 mg to 0.6 mg single dose, followed by 0.3 mg one hour later; do not repeat for 3 days 3

Moderate CYP3A4 Inhibitors (diltiazem, verapamil, erythromycin, fluconazole):

• Prophylaxis: Reduce from 0.6 mg twice daily to either 0.3 mg twice daily or 0.6 mg once daily 3
• Acute flare: Use 1.2 mg single dose only; do not repeat for 3 days 3

P-gp Inhibitors (cyclosporine, ranolazine):

• Same dose reductions as strong CYP3A4 inhibitors 3

Pediatric Dosing (FMF Only)

Colchicine is not recommended for pediatric gout 3. For Familial Mediterranean Fever in children ≥4 years:

• Ages 4-6 years: 0.3-1.8 mg daily 3
• Ages 6-12 years: 0.9-1.8 mg daily 3
• Ages >12 years: 1.2-2.4 mg daily 3

Doses may be given once daily or divided twice daily 3.

Key Safety Considerations

Gastrointestinal symptoms (especially diarrhea) are the first sign of colchicine toxicity—reduce dose immediately if these occur 5. The narrow therapeutic window makes dose adjustments critical in renal impairment, hepatic impairment, and with interacting drugs 2, 7.

Therapeutic drug monitoring has limited clinical value, as colchicine concentrations do not consistently correlate with efficacy or adverse events 8.